On the stock market since 1997, it operates in the world of health and science. It has 58 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $63.4M in the vault; even if every debt were paid off, $23.4M would remain.
A loss of $30.4M against $118.7M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 2.1 years. After that, the company needs to find new money.
On our five-subject report card, ASRT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ASRT is a small company that closed last year at a loss. The road back to profit runs through spending discipline.